PhD candidate 'Optimal treatment with targeted therapy in cancer'
The department of Medical Oncology together with the pharmacy at Radboudumc have a longstanding collaboration to optimize targeted anticancer therapy for patients with cancer. Alternative treatment strategies with clinically available agents to improve outcome for patients are being studied.
The current PhD-project is based on our prior studies in which we measured tyrosine kinase inhibitors (TKIs) concentrations directly in tumors from patients and studied short exposure to high doses of a TKI. We found promising antitumor activity of this alternative strategy. In the current PhD-project, we aim:
- To get more insight in the mechanism of action of high dose TKI treatment.
- To test other treatment strategies (dosing, schedules) for other TKIs.
- To test combination strategies of alternatively dosed TKIS in combination with chemotherapy and immunotherapy for further clinical development.
We are looking for motivated candidates with a background in biomolecular sciences / cell biology. Candidates should have a genuine interest to develop and test preclinical models for clinical studies. Additionally, applicants should have excellent English oral, writing and presentation skills.
The department of Medical Oncology is leading in translational cancer research and investigator initiated early phase clinical trials. The pharmacy department is worldwide recognized for its innovation of treatment strategies with targeted agents in oncology. The departments are embedded in the Radboud Institute for Health Sciences in the Netherlands, a leading European research school providing an outstanding research setting for the Radboud University.
Research within the departments of Medical Oncology and Pharmacy aims to improve outcome of patients with mostly advanced cancer. An important activity of the departments is the translation of preclinical findings into clinical applications. The research is focused on the development of personalized medicine with targeted agents and immunotherapy as well as improvement of the quality of life of patients with cancer. Preclinical research methods such as imaging, molecular, cell biological, immunological, and computational techniques are being used.
Radboudumc strives to be a leading developer of sustainable, innovative and affordable healthcare to improve the health and wellbeing of people and society in the Netherlands and beyond. This is the core of our mission: To have a significant impact on healthcare. To get a better picture of what this entails, check out our strategy.
Read more about what it means to work at Radboudumc and how you can do your part.
- We offer a temporary contract for 4 years, 36 hours a week.
- Scale 10A: max € 42220 gross per year at full employment (incl. vacation bonus and end of year payments).
The candidate is offered a full-time position for 4 year PhD program. The research group will provide the candidate with necessary support on all aspects of the project. After a positive evaluation at 12 months, the contract will be extended.
Upon commencement of employment we require a certificate of conduct (Verklaring Omtrent het Gedrag, VOG) and there will be, depending on the type of job, a screening based on the provided cv. Radboud university medical center’s HR Department will apply for this certificate on your behalf.
Read more about the Radboudumc employment conditions and what our International Office can do for you when moving to the Netherlands.
Comments and contact information
All additional information about the vacancy can be obtained from Prof. Henk Verheul, medical oncologist via Henk.Verheul@radboudumc.nl or from Dr. Nielka van Erp, pharmacist via Nielka.vanErp@radboudumc.nl or +31 (0)24 361 03 53.
Please apply before September 2, 2019 via the application form.
Recruitment agencies are asked not to respond to this job posting.